首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNL2 |
| Uniprot No | Q8IZJ0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-200aa |
| 氨基酸序列 | VPVARLHGALPDARGCHIAQFKSLSPQELQAFKRAKDALEESLLLKDCRC HSRLFPRTWDLRQLQVRERPMALEAELALTLKVLEATADTDPALVDVLDQ PLHTLHHILSQFRACIQPQPTAGPRTRGRLHHWLYRLQEAPKKESPGCLE ASVTFNLFRLLTRDLNCVASGDLCV |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNL2重组蛋白的3篇参考文献，按文献名称、作者和摘要内容概括列出：
---
1. **文献名称**：*Production and characterization of recombinant human interferon lambda2 (IFN-λ2/IL-28B)*
**作者**：Dellgren C., et al.
**摘要**：本研究报道了在大肠杆菌系统中高效表达和纯化重组人IFNL2蛋白的方法，并验证了其生物活性。通过体外实验证实，IFNL2能够激活STAT1/STAT2信号通路，并诱导干扰素刺激基因(ISGs)的表达，提示其在抗病毒治疗中的潜在应用。
2. **文献名称**：*IFN-λ2 (IL-28B) mediates antiviral protection through a distinct class II cytokine receptor complex*
**作者**：Kotenko S.V., et al.
**摘要**：该研究阐明了IFNL2通过结合独特的II类细胞因子受体复合物(IFNLR1/IL-10Rβ)激活下游信号通路，进而抑制丙型肝炎病毒(HCV)复制的机制。重组IFNL2蛋白在肝细胞模型中表现出与IFNL3相似的抗病毒活性，但受体亲和力存在差异。
3. **文献名称**：*Differential activity of type III interferon variants in innate immune priming*
**作者**：Mordstein M., et al.
**摘要**：研究比较了IFNL家族成员(包括重组IFNL1、IFNL2和IFNL3)在调节上皮细胞先天免疫应答中的作用。结果显示，重组IFNL2可显著增强细胞对RNA病毒的抗性，但其诱导的免疫基因表达谱与IFNL3存在部分差异，提示功能上的亚型特异性。
---
**备注**：IFNL2研究相对较少，以上文献可能涉及早期机制探索，近年研究更集中于IFNL3/4(如IL-28B/IL-29)与疾病关联。如需更新文献或扩展应用场景(如癌症、纤维化)，建议结合关键词“IFNL2 recombinant protein therapeutic”进一步检索。
Interferon lambda 2 (IFNL2), a member of the type III interferon (IFN-λ) family, plays a critical role in innate antiviral immunity. Discovered in the early 2000s, the IFN-λ family includes four subtypes (IFNL1-4) that signal through a heterodimeric receptor complex composed of IL-10Rβ and IFNLR1. Unlike type I interferons, which are broadly expressed, IFN-λs exhibit tissue-specific activity, primarily targeting epithelial cells and hepatocytes. This localized response minimizes systemic inflammation, making IFNL2 a promising candidate for antiviral therapies with fewer side effects.
Recombinant IFNL2 protein is produced using genetic engineering techniques, often in bacterial, yeast, or mammalian expression systems. By inserting the IFNL2 gene into host cells, researchers generate purified, bioactive protein for experimental and therapeutic applications. Its antiviral properties are particularly relevant in combating RNA viruses, including hepatitis C virus (HCV) and coronaviruses. Studies highlight its ability to induce interferon-stimulated genes (ISGs), inhibit viral replication, and modulate immune responses.
Beyond virology, IFNL2 recombinant protein is studied for its immunoregulatory roles in chronic inflammatory diseases, cancer, and autoimmune conditions. Its unique receptor specificity and cell-targeted action have spurred interest in developing IFN-λ-based therapies as alternatives to conventional type I IFNs. However, genetic polymorphisms near the IFNL2/3 locus influence clinical outcomes, underscoring the need for personalized approaches. Ongoing research continues to unravel its dual role in antiviral defense and immune homeostasis, positioning IFNL2 as a versatile tool in both basic science and translational medicine.
×
